SearchDictionaryMobileLogin

Chien-Ching Hung Selected Research

Highly Active Antiretroviral Therapy (HAART)

05/2008Cytomegalovirus retinitis and immune recovery uveitis in AIDS patients treated with highly active antiretroviral therapy in Taiwanese.
11/2007Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy.
09/2007Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
04/2007Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
02/2007Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
10/2006Changes in the clinical spectrum of opportunistic illnesses in persons with HIV infection in Taiwan in the era of highly active antiretroviral therapy.
08/2006Improved survival of persons with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy in Taiwan.
01/2006Effect of prolonged HAART on oral colonization with Candida and candidiasis.
10/2005Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study.
11/2004Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections.
07/2004Successful discontinuation of secondary prophylaxis for histoplasmosis after highly active antiretroviral therapy.
12/2003Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy.
12/2003Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection.
12/2003Recurrence of tuberculosis in HIV-1-infected adults treated after rifamycin-based treatment and highly active antiretroviral therapy.
03/2002Discontinuation of secondary prophylaxis for penicilliosis marneffei in AIDS patients responding to highly active antiretroviral therapy.

Articles by Research Topic

Disease

7Infection
09/2008 - 03/2003
2Acquired Immunodeficiency Syndrome (AIDS)
05/2008 - 03/2002
2HIV Infections (HIV Infection)
10/2006 - 12/2003
2Tuberculosis
12/2003 - 12/2003
1Amebic Dysentery (Amoebic Dysentery)
09/2008
1Uveitis
05/2008
1Cytomegalovirus Retinitis
05/2008
1Hepatitis B
11/2007
1Cryptococcosis
09/2007
1Hypersensitivity (Allergy)
09/2007
1Bacteremia
09/2007
1Viremia
02/2007
1Candidiasis (Moniliasis)
01/2006
1Herpes Zoster
10/2005
1Opportunistic Infections (Opportunistic Infection)
11/2004
1Histoplasmosis
07/2004
1Meningeal Tuberculosis (Tuberculous Meningitis)
12/2002

Drug/Important Bio-Agent (IBA)

1AntigensIBA
09/2008
1abacavir (Ziagen)FDA Link
09/2007
1HLA-B Antigens (HLA-B)IBA
09/2007
1galactomannanIBA
09/2007
1rifamycin SVIBA
12/2003
1liposomal amphotericin BFDA Link
10/2003
1efavirenz (Sustiva)FDA Link
03/2003
1Reverse Transcriptase InhibitorsIBA
03/2003

Therapy/Procedure

15Highly Active Antiretroviral Therapy (HAART)
05/2008 - 03/2002
1Transplantation (Transplant Recipients)
10/2003
1Drug Therapy (Chemotherapy)
12/2002